Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial

J Clin Oncol. 2024 May 16:JCO2400279. doi: 10.1200/JCO.24.00279. Online ahead of print.

Authors

David J Einstein^{1

2}, Meredith M Regan^{2

3}, Julia S Stevens⁴, David F McDermott^{1

2}, Ravi A Madan⁵

Affiliations

¹ Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
² Harvard Medical School, Boston, MA.
³ Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.
⁴ Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA.
⁵ Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

PMID: 38754067
DOI: 10.1200/JCO.24.00279

Abstract

What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.